Sharemaestro Newsreel

EU panel recommends Trodelvy-Keytruda after 35% lower progression-or-death risk

Gilead Sciences announced that the European Medicines Agency's CHMP has recommended marketing authorization for Trodelvy in combination with Keytruda for first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. This recommendation is based on the ASCENT-04/KEYNOTE-D19 study, which showed a 35% reduced risk of disease …

This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly

Billionaire Christian Angermayer, inspired by a personal mushroom trip, has sold his psychedelic biotech firm AtaiBeckley to Eli Lilly for $2.8 billion, with potential additional milestone payments. Angermayer's 15% stake is set to net him $360 million (pre-tax). This acquisition, the largest in the …

Bristol Myers Squibb Company $BMY Stake Raised by Sei Investments Co.

Sei Investments Co. increased its stake in Bristol Myers Squibb (NYSE:BMY) by 8.2% in the first quarter, bringing its total holdings to over 2.19 million shares valued at $133 million. Several other institutional investors also adjusted their positions in BMY. Analysts have a mixed …

Grifols, S.A. (GRFS) Stock Price, News, Quote & History

This Yahoo Finance article provides a comprehensive overview of Grifols, S.A. (GRFS), a company specializing in plasma-derived medicines and diagnostic equipment. It details the company's stock performance, key financial metrics, business segments, and recent news, alongside analyst insights and comparison with similar pharmaceutical companies.

BMY|Bristol-Myers Squibb Co|Price:63.745|Chg%:-1.095

Compound Planning Inc. Buys 7,818 Shares of Amgen Inc. $AMGN

Compound Planning Inc. increased its stake in Amgen Inc. by 83.4% during Q1, now owning 17,195 shares valued at $6.05 million. Other institutional investors like Norges Bank, Capital World Investors, and State Street Corp also significantly increased their holdings in Amgen. The article also …

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a preliminary U.S. court injunction to block Eli Lilly's advertising for its obesity and diabetes drugs, Zepbound and Mounjaro. Novo Nordisk claims Lilly's ads are misleading, using "outdated studies" and comparing the highest doses of Lilly's drugs to lower doses …

Amgen Statement on FDA Data Submission for TAVNEOS® (avacopan)

Amgen has submitted extensive data and analyses to the U.S. Food and Drug Administration (FDA) to support its request for a hearing regarding TAVNEOS (avacopan), aiming to preserve access to this treatment for severe active ANCA-associated vasculitis (AAV) in the U.S. The company strongly …

ABBV|AbbVie Inc|Price:256.910|Chg%:+3.610

AbbVie Inc. (ABBV) shows stable fundamentals and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. The stock is a high dividend payer and exhibits high institutional ownership. While the stock price is expected to trend upwards in the medium …

Bristol Myers Squibb Takes Drugmaker Week Rank at 92.6% of Its Yearly Range

BMY added 5.5% in the latest week and led its US Drug Manufacturers - General group, but Sharemaestro Market Dynamics have not fully confirmed the move.

Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit.

This article discusses a patent dispute where Enanta Pharmaceuticals lost to Pfizer despite filing first, due to a single digit error in their provisional patent application. The Federal Circuit affirmed that Enanta's patent for a coronavirus protease inhibitor was invalid because the provisional application …

Bank of Nova Scotia Has $110.56 Million Stock Position in Amgen Inc. $AMGN

Bank of Nova Scotia reduced its stake in Amgen Inc. by 15.8% in Q1, selling 58,745 shares and retaining 314,227 shares valued at approximately $110.6 million. Amgen's recent earnings exceeded expectations, with EPS of $5.15 and revenue of $8.62 billion, a 5.8% increase year-over-year. …

Genmab, AbbVie Clarify Epcoritamab Phase 3 Trial Missed Primary Endpoint

Genmab and AbbVie issued a clarification regarding their Phase 3 EPCORE DLBCL-1 trial, stating that overall survival was the sole U.S. primary endpoint and it was not met. This clarification was deemed necessary due to interpretive ambiguity in earlier disclosures, highlighting the complexities of …

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

Three analysts have issued bullish sentiments on healthcare companies Johnson & Johnson (JNJ), Helus Pharma (HELP), and Nektar Therapeutics (NKTR). RBC Capital maintained a Buy rating on JNJ with a $287 price target, Bloom Burton maintained a Buy on HELP with a $47 price …

Sanofi ends amLitelimab program in atopic dermatitis amid portfolio review

Sanofi has discontinued the development of its anti‑OX40L monoclonal antibody, amLitelimab, for moderate to severe atopic dermatitis, concluding that its efficacy and safety data do not warrant regulatory submissions or significant improvement over existing treatments. This decision is part of a broader strategic portfolio …

AstraZeneca PLC expected to post earnings of $2.54 a share - Earnings Preview

AstraZeneca PLC is projected to report earnings of $2.54 per share. This information comes from a Refinitiv earnings preview.

Eli Lilly and Company Price Today | XLLY Live Price, Chart & Market Cap

This article provides real-time pricing and market information for Eli Lilly and Company (token XLLY) on the OKX platform, showing its current price as $1,190.22 USD. It also covers the all-time high of $1,191.7 hit on July 24, 2026, and offers guides on how …

Amarin Corp - ADR (AMRN) Fundamental & Financial Data

This article provides fundamental and financial data for Amarin Corp - ADR (AMRN). It details current stock metrics such as market capitalization, current price, PE ratio, dividend yield, and 52-week high/low. The page also includes recent news headlines related to pharmaceutical companies and discussions …

Revenue Beat: Novartis AG Beat Analyst Estimates By 5.7%

Novartis AG announced interim results showing revenues of US$28 billion, a 5.7% beat on analyst predictions, with statutory earnings per share at US$1.71, in line with forecasts. Despite the revenue beat, analysts haven't significantly altered their 2026 forecasts, maintaining revenue estimates at US$57.5 billion …

Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts

Bristol Myers Squibb (BMY) saw a 1.05% gain, closing at $61.40, while the broader market declined. The stock has increased by 10.47% over the past month, outperforming both the Medical sector and the S&P 500. Analysts anticipate an 8.9% year-over-year earnings growth for its …

Eli Lilly Delay Puts Madrigal Stock In Focus For Obesity Drug Investors

Eli Lilly's delay in the approval timeline for its next-generation obesity drug, retatrutide, until Q1 2027, despite promising clinical data, is refocusing investor attention on other obesity and diabetes-related therapies. This article examines three companies—Madrigal Pharmaceuticals (MDGL), Corcept Therapeutics (CORT), and Protagonist Therapeutics (PTGX)—and …

MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA)

This article provides an overview of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) financial actuals and estimates as presented on TradingView. It covers past stock performance, analyst forecasts, historical high and low prices, market capitalization, and upcoming earnings dates. The content also addresses frequently asked questions about …

How Investors May Respond To Pfizer (PFE) Prostate Cancer Combo Drug Label Expansion Push

Pfizer's TALZENNA plus XTANDI combination drug for prostate cancer has received Priority Review from the FDA for a label expansion into earlier-stage treatment. This move aligns with Pfizer's strategy to focus on high-value oncology therapies as COVID-19 revenues decline and patent expirations loom. While …

What Amgen (AMGN)'s Blocked Colorado Enbrel Price Cap Means For Shareholders

A federal judge recently blocked Colorado's aggressive plan to cap the price of Amgen's arthritis drug Enbrel, easing a near-term pricing concern for the company. While this reduces uncertainty for Enbrel, it doesn't eliminate the broader risk of future drug pricing reforms and reimbursement …

Popular insulin product enters shortage as other pens leave market

Sanofi's Lantus Solostar pen, a popular long-acting insulin product, is experiencing supply issues due to increased demand and broader market dynamics, prompting users to struggle with finding the medication. While not officially designated an FDA shortage, the company anticipates the situation will improve in …

Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial

Genmab and AbbVie announced that their lymphoma drug, epcoritamab, did not meet the primary endpoint in a Phase 3 clinical trial. The trial aimed to evaluate the drug's efficacy in patients with diffuse large B-cell lymphoma (DLBCL). This outcome is a setback for the …

Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer

Pfizer's high 7% dividend yield might seem unsustainable due to a high payout ratio, but the company's robust pipeline and strategic growth initiatives suggest its dividend program is more secure than it appears. Despite past revenue declines, new drug approvals like Padcev's expanded use …

Amgen (AMGN) Rises As Market Takes a Dip: Key Facts

Amgen (AMGN) stock rose by 1.48% to $371.47, outperforming the down-trending S&P 500, Dow, and Nasdaq in a recent trading session. The biotech giant is expected to report Q3 2026 earnings per share of $5.6 (a 6.98% decrease year-over-year) and revenue of $9.45 billion …

Breaking News: Eli Lilly pays $38M to secure land for massive West Creek pharma facility

Eli Lilly recently acquired a 227-acre parcel in Goochland County for $38.39 million, marking a significant step towards its planned $5 billion, 1 million-square-foot manufacturing facility in West Creek. This facility is expected to produce bioconjugate and monoclonal antibody medicines, create 650 permanent jobs, …

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie clarified that overall survival (OS) was the sole U.S. primary endpoint for the Phase 3 EPCORE DLBCL-1 trial, which unfortunately did not meet this endpoint, indicating no statistically significant improvement in OS. The study evaluated epcoritamab in adults with relapsed or …

Epcoritamab U.S. Lymphoma Trial Does Not Meet Survival Endpoint

Genmab and AbbVie announced that their Phase 3 EPCORE® DLBCL-1 trial, evaluating epcoritamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival in the U.S. market. While epcoritamab is already approved under accelerated pathways for similar conditions, …

Grifols stock stabilizes as investors weigh Q1 2024 earnings and leverage metrics

Grifols stock shows stability as investors evaluate its Q1 2024 earnings, marked by improved operating performance but persistently high leverage. The company reported increased revenue and EBITDA, driven by its Bioscience division, and reiterated its commitment to debt reduction and cash generation. While progress …

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

Eli Lilly and Company announced positive topline results from two pivotal Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, for its investigational drug retatrutide. The triple hormone receptor agonist demonstrated substantial weight loss and improved glycemic control in adults with obesity, type 2 diabetes, and established …

Lilly Targets Early 2027 Filing for Next Obesity Drug

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) fell 0.35% in premarket after reporting positive results from two further Phase 3 trials of retatrutide and confirming it will submit a biologics license application to the FDA in the first quarter of 2027. The …

Eli Lilly's Retatrutide Clears Two More Trials Ahead of 2027 Filing

This article first appeared on GuruFocus. Eli Lilly (LLY, Financials), a pharmaceutical firm that focuses on diabetes, obesity and other chronic diseases, said it aims to petition for regulatory approval of retatrutide in the first quarter of 2027 after the medicine succeeded in two …

DOL Brief Sides With Bristol-Myers in PRT Appeal

The U.S. Department of Labor filed an amicus brief supporting Bristol-Myers Squibb in an appeal, arguing that retirees lack Article III standing to sue over pension risk transfers if they continue to receive full benefits. This action, along with a similar brief for Lockheed …